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OBJECTIVE—To test the effect of an automated system providing real-time estimates of
HbA1c, glucose variability, and risk for hypoglycemia.
RESEARCH DESIGNANDMETHODS—For1year, 120 adultswith type 1diabetes(69
female/51 male, age = 39.1 [14.3] years, duration of diabetes 20.3 [12.9] years, HbA1c =8 . 0
[1.5]), performed self-monitoring of blood glucose (SMBG) and received feedback at three in-
creasingly complex levels, each continuing for 3 months: level 1—routine SMBG; level 2—add-
ing estimated HbA1c, hypoglycemia risk, and glucose variability; and level 3—adding estimates
of symptoms potentially related to hypoglycemia. The subjects were randomized to feedback
sequences of either levels 1-2-3 or levels 2-3-1. HbA1c, symptomatic hypoglycemia, and blood
glucose awareness were evaluated at baseline and at the end of each level.
RESULTS—For all subjects, HbA1c was reduced from 8.0 to 7.6 from baseline to the end of
study(P=0.001).ThiseffectwasconﬁnedtosubjectswithbaselineHbA1c.8.0(from9.3to8.5,
P , 0.001). Incidence of symptomatic moderate/severe hypoglycemia was reduced from 5.72 to
3.74 episodes/person/month (P = 0.019), more prominently for subjects with a history of severe
hypoglycemia (from 7.20 to 4.00 episodes, P = 0.008) and for those who were hypoglycemia
unaware (from 6.44 to 3.71 episodes, P = 0.045). The subjects’ ratings of the feedback were
positive, with up to 89% approval of the provided features.
CONCLUSIONS—Feedback of SMBG data and summary SMBG-based measures resulted in
improvement in average glycemic control and reduction in moderate/severe hypoglycemia.
These effects were most prominent in subjects who were at highest risk at the baseline.
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ntensive insulin treatment attempting
to approximate near-normal levels of
glycemia markedly reduces chronic
complications of type 1 diabetes (1,2)
but may risk potentially life-threatening
severe hypoglycemia (SH)—ar e s u l to f
imperfectinsulinreplacement(3).Conse-
quently, hypoglycemia has been identi-
ﬁed as the primary barrier to optimal
diabetes management (4). Thus, people
with type 1 diabetes mellitus face a life-
longbehaviorallycontrolledoptimization
problem: to maintain strict glycemic con-
trol without increasing their risk for
hypoglycemia (5). Handling these com-
plex and demanding aspects of diabetes
management requires motivation, goal
setting, and accurate assessment of risk
of hypoglycemia. It is therefore reason-
able to expect that feedback that can be
motivating (e.g., tracking progress in
HbA1c on a weekly basis) and at the
same time informative about risks and
symptoms of hypoglycemia could be a
useful tool assisting the improvement of
glycemic control. Such feedback should
be available in patients’ natural environ-
ment and should use routine data, such
as self-monitoring of blood glucose
(SMBG).
Most contemporary home SMBG de-
vicesprovideaccuratebloodglucose(BG)
readings and are capable of storing a
signiﬁcant number of BG readings (typi-
cally.150).Thecurrentstudygaugesthe
utility of three levels of SMBG-based
feedback to patients with type 1 diabetes:
level 1—routine SMBG alone; level 2—
r o u t i n eS M B Gp l u sS M B G - b a s e de s t i -
mated of HbA1c, risk for hypoglycemia,
and glucose variability; and level 3—add-
ingsymptomratingsandtheevaluationof
symptoms presumably related to hypo-
glycemia in level 2 feedback.
The theoretic background for this
approach can be traced to previous inter-
ventions based on BG feedback that have
been shown to improve clinical outcomes
in type 1 diabetes. For example, it is well
documentedthattheavoidanceoflowBG
events (,70 mg/dL) for a few weeks can
improvesymptomperceptionandreverse
hypoglycemia unawareness (6,7). Sec-
ond,ourgrouphasshowninseveralstud-
ies that blood glucose awareness training
(BGAT)—a psycho-behavioral interven-
tion for people with type 1 diabetes based
on systematic feedback about BG levels
and accuracy of symptom perception—
has positive effects. These include
improvement in low BG detection,
knowledge, decision-making, and re-
duced events, such as SH (8–10). The as-
sumption of these interventions is that
providing patients with systematic feed-
back provides information needed to
make adjustments in diabetes manage-
ment that improve self-regulation.
The computational background for
the estimates of level 2 feedback has been
presented in a series of studies showing
that speciﬁc risk analysis of SMBG data
could capture long-term trends toward
increased risk for hypoglycemia (11,12)
and identify 24-h periods of increased
risk for hypoglycemia (13,14). These
analyses were based on recognition of
a speciﬁc asymmetry of the BG measure-
mentscaleandonanonlineartransforma-
tioncorrectingthisasymmetry(15,16).In
essence, we have developed and tested
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ORIGINAL ARTICLEalgorithms using SMBG to evaluate glyce-
mic control (17) and glucose variability
(18)intype1diabetes.Thecomputational
background for the symptom estimates of
level 3 feedback can be traced to the Sto-
chasticModelofSelf-RegulationBehavior,
which gives a mathematic description to
the feedback pattern internal condition:
symptom perception/awareness, ap-
praisal, and self-regulation decision (19).
On the basis of these theoretic and
computational developments, we hy-
pothesized that readily available auto-
mated feedback of summary parameters
of glycemic control, such as estimated
HbA1c, risk for hypoglycemia, and hypo-
glycemic symptom speciﬁcity, would en-
hance the control of type 1 diabetes. To
test this hypothesis, we designed a feed-
back system residing in a handheld com-
puter(HHC) given to patientswith type1
diabetesintheirnaturalenvironment.We
then evaluated the efﬁcacy of this system
for improving HbA1c and reducing risks
for hypoglycemia.
RESEARCH DESIGN AND
METHODS
Subjects
A total of 120 adults with type 1 diabetes
were recruited through regional advertis-
ing.Inclusioncriteriawereage$18years,
type 1 diabetes deﬁned by the American
Diabetes Association criteria or physician
judgment, and willingness to participate
inthestudyforupto12monthsperform-
ing SMBG four to ﬁve times per day. The
demographic and biometric characteris-
tics of the participants are presented in
Table 1.
Of the 120 individuals enrolled in the
study, 97 completed the entire 1-year
protocol. The observed 19.2% attrition
rate was lower than the anticipated 25%
attrition rate used to power the study.
Thirteen subjects dropped out during the
ﬁrst phase of the study (SMBG alone; see
next paragraph), three subjects dropped
out during the second phase of the study,
and seven subjects dropped out during
the third phase of the study.
Procedure
The study was approved by the institu-
tional review board of the University of
Virginia and registered as a clinical trial
(institutional review board 12126, Clini-
cal Trials.gov ID NCT00315939). After
recruitment, subjects signed consent
forms, completed background question-
naires,andwererandomizedintogroupA
or group B matched by gender, age, and
baseline HbA1c.A ss e e ni nT a b l e1 ,t h e r e
were no signiﬁcant between-group differ-
ences on history of SH, hypoglycemia
awareness, and frequency of SMBG:
Group A began with routine SMBG alone
(level 1),followed sequentiallybylevels 2
and 3. Group B began with level 2, fol-
lowed by level 3 and then level 1. Each
level continued for 3 months and pro-
ceeded as follows: level 1 was routine
SMBG.SubjectsweregivenLifeScanOne-
Touch UltraSmart meters (LifeScan Inc.,
Milpitas,CA)and free strips, andasked to
perform SMBG four to ﬁve times per day.
No additional instructions about the tim-
ing of SMBG or the interpretation of the
data were given. No changes to treatment
were recommended. At each visit, the
subject was only asked about any health
concerns or any new medications or
change in insulin. This information was
recordedbutnotusedforfeedback.Thus,
level 1 should be regarded as a control
condition, which was different from rou-
tine SMBG only because subjects were
enrolled in a study and given free test
strips.
Level 2 retained level 1, but an HHC
was given to the subjects, programmed to
estimate HbA1c (20), risk for hypoglycemia
(LowBGIndex)(11),andglucosevariabil-
ity (Average Daily Risk Range) (18) using
previouslypublishedalgorithms.Thesub-
jects were asked to carry the HHC and
enter all their glucose readings when per-
forming SMBG. The estimates of HbA1c
were updated weekly, and the estimates
of risk for hypoglycemia and glucose var-
iability were updated at each SMBG entry.
Detailed instructions were provided on
themeaningofthesedifferenttypesofglu-
cosefeedback;thestudystaffwasavailable
to answer any questions.
Level 3 retained level 2, but the HHC
asked subjects to provide symptom rat-
ings when BG was low (,3.9 mmol/L)
and at an equal number of matching
euglycemic readings. From these data, the
HHC estimated a set of potentially signif-
icant symptoms of hypoglycemia for each
individual, using an iterative algorithm
following apreviouslypublished symptom
signiﬁcance estimation procedure (19).
The patient manual for the HHC program
is provided in supplementary data.
With this design, the study was split
into three sequential 3-month blocks of
time: In the ﬁrst 3 months, subjects from
group A served as controls to group B
assessing the effectiveness of SMBG
alone versus level 2 feedback; the sub-
sequent3monthscontrastedlevel2with
level3feedback,andinthelast3months
contrasted level 3 feedback with SMBG
alone.
Metrics
HbA1c was assessed at the University of
Virginia laboratory at baseline and after
each level of feedback. To assess hypogly-
cemic symptoms and accuracy of low BG
detection, four 1-month HHC assess-
ments were performed, including one at
Table 1—Demographic, biometric, and diabetes history characteristics of participants
Group A Group B All subjects
P level
Av s .B
Age (years) – mean (SD) 40.65 (14.84) 37.61 (13.78) 39.15 (14.35) 0.248
Gender (male/female) 26/33 25/36 51/69 0.735
Baseline HbA1c – mean (SD) 7.96 (1.49) 8.02 (1.49) 7.99 (1.48) 0.846
Duration of diabetes (years) 20.93 (13.03) 19.61 (12.89) 20.28 (12.92) 0.577
No. of severe hypoglycemic episodes
in the past year 1.23 (2.25) 1.07 (2.55) 1.15 (2.396) 0.714
Percentage of subjects reporting SH
in the past year 0.34 (0.48) 0.31 (0.46) 0.32 (0.47) 0.650
Hypoglycemia awareness
(aware/unaware) 35/26 38/21 73/47 0.434
No.ofSMBGreadingsperdayreported
retrospectively at screening 4.92 (2.1) 4.46 (1.55) 4.69 (1.84) 0.172
No. of SMBG readings per day during
level 1 feedback 4.89 (2.03) 4.75 (1.37) 4.82 (1.73) 0.684
No. of SMBG readings per day during
level 2 feedback 5.34 (2.49) 4.76 (1.36) 5.09 (2.07) 0.135
No. of SMBG readings per day during
level 3 feedback 5.02 (2.58) 4.40 (1.40) 4.74 (2.13) 0.137
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each of the levels of feedback. To elimi-
nate assessment bias, these assessments
were identical throughout all stages of
the study. Each assessment required sub-
jects to complete 70 HHC trials over a
month, with each trial asking them to
rate their symptoms and estimate BG on
the basis of symptoms before SMBG.
In parallel, diaries of SH were com-
pletedusingan automated Internet-based
system, previously used for other studies
(21). Once subjects logged in, they were
able to see which diaries needed to be
completed and then proceed through
the diary questions. Responses were
stored on our Health Insurance Portabil-
ity and Accountability Act-compliant
server. SH was deﬁned as “Blood glucose
so low that you could not treat yourself
because you were stuporous or uncon-
scious.” The system also recorded epi-
sodes of moderate hypoglycemia (MH),
deﬁned as “Blood glucose so low that
you could not continue with your activi-
tiesbecauseyoucouldnotthinkclearlyor
lost yourcoordination,butyoucouldstill
treat yourself.”
Ratings of feedback
After completing level 2, subjects were
given the opportunity to evaluate the
feedback presented to them by the
HHC. Questions about HbA1c feedback
included Q1: “Do you think this feature
will help you lower your HbA1c levels in
the long run?” and Q2: “Do you want
to see your HbA1c insight on a weekly
basis?” Questions regarding glucose var-
iability feedback included Q3: “Do you
feel this feature helped you manage
your diabetes?” and Q4: “Do you want
to be presented with the Variability in-
sight number on a weekly basis?” Ques-
tions regarding risk for hypoglycemia
included Q5: “Would you look at this
feature on a regular basis?” and Q6: “Do
you feel more comfortable knowing you
will be warned of your risk of hypoglyce-
mia?” Each question could be answered
“Yes,”“ No,” or “Not sure.”
Statistical analysis
The primary outcomes of this study were
HbA1c and frequency of SH/MH as recor-
ded independently from SMBG using the
Internet system. The data for subjects
who dropped out during the study were
handled according to the intention-to-
treatprinciple,using “dropout”asafactor
in the analysis and adjusting signiﬁcance
levels accordingly. Repeated-measures
ANOVA was used to compare HbA1c
and SH data, as well as the data from the
four HHC assessments of the study.
Group variables deﬁned at the baseline
wereusedintheanalyses,includingstudy
groups A and B; HbA1c group: ,8.0 vs.
.8.0 baseline HbA1s; SH group: history
versus no history of SH; and hypoglyce-
mia awareness group: aware versus un-
aware subjects. Secondary analyses
included average BG, BG range, and met-
rics of frequency of hypo- and hypergly-
cemic episodes recorded by SMBG.
Subjects’abilitytoestimatetheirBGaccu-
ratelyanddetecthypoglycemiaon theba-
sis of symptoms was assessed by the
Accuracy Index, deﬁned as percentage
in A minus C, D, E zones on the Clarke
Error-Grid Analysis (22,23), and by the
percent detection of BGs ,3.9 mmol/L.
RESULTS
Frequency of self-monitoring of
blood glucose
As presented in Table 1, the retrospec-
tively assessed frequency of SMBG during
thescreening visitbaseline was4.69read-
ings/subject/day, which was not statisti-
cally different from the subsequently
observed frequency of SMBG. No between-
group differences were observed. How-
ever, the frequency of SMBG in subjects
whohadbaselineHbA1c$8.0was4.26→
4.40 → 4.33 → 4.1 readings/day at base-
lineandduringfeedbacklevels1,2,and3,
respectively,whichwasconsistentlylower
thaninsubjectswithHbA1c,8.0:F=8.8,
P = 0.004.
HbA1c
Throughout the study, for all subjects
regardlessofattrition,HbA1cwasreduced
from7.99(1.48)atbaselineto7.69(1.30)
after feedback level 1, to 7.69 (1.33) after
feedbacklevel2, to 7.58(1.08) after feed-
back level 3 (F = 5.6, P = 001). Attrition
was a signiﬁcant factor for the analysis of
HbA1c—subjects who dropped out had
signiﬁcantly higher HbA1c at baseline
than those who completed the study,
9.07 (2.05) vs. 7.73 (1.19), P , 0.001.
By retaining the last known HbA1c for
those who quit the study, these averages
were adjusted to 7.99 → 7.80 → 7.85 →
7.83, and the signiﬁcance of the feedback
was assessed after this adjustment: F =
5.6, P = 0.001.
As presented in Fig. 1A, the reduc-
tion in HbA1c was entirely accounted for
by those subjects who had baseline
HbA1c $8.0. For the rest of the subjects,
HbA1c level did not change, which resulted
in a signiﬁcant interaction: F = 7.0, P ,
0.0005.
Additional analyses revealed that the
order of feedback initiation did not have
signiﬁcant effect on the progression of
HbA1cimprovement:Thelargestdecrease
wasregisteredaftertheﬁrsttreatmentses-
sion, regardless of whether this session
included level 1 or 2 feedback: HbA1c
for group A changed from 7.99 to 7.76,
whereas for group B the change was from
8.0 to 7.9 (F = 0.9, NS) from the begin-
ning to the end of study.
Severe and moderate hypoglycemia
During the baseline monitoring period,
the participants reported 0.09 SH epi-
sodes/person/month, whereas during the
last monitoring period (after feedback
level 2) there were 0.02 SH episodes/
person/month. This difference was signif-
icant: F = 15.3, P , 0.001. This effect
was most prominent for subjects who
reported a history of SH (from 0.32 to
0.04 SH episodes/subject/month, P ,
0.001) and for those who reported hypo-
glycemia unawareness at baseline (from
0.25 to 0.03 SH episodes/subject/month,
P = 0.001) (Fig. 1B). However, the pro-
gression of the improvement in SH regu-
lation was substantially different from
the progress in HbA1c. As seen in Fig. 1A,
HbA1c decreased immediately after the
ﬁrst level of feedback and retained similar
levels thereafter. In contrast, as seen in
Fig. 1B, SH increased (although not sta-
tistically signiﬁcantly) from baseline to
level 1 (SMBG alone), and then gradually
decreased throughout the more exten-
sive feedback periods. There were no
between-group differences: In group A,
SH episodes decreased from 0.09/subject/
month to 0.023 episodes/subject/month;
in group B, this change was from 0.09 to
0.019 episodes.
Episodes of MH also decreased, from
5.63/person/month in the beginning of
the study to 3.72/person/month at the
end (F = 5.3, P = 0.02). This effect was
moreprominentinsubjectswithahistory
o fS H( f r o m6 . 8 8t o3 . 9 6e p i s o d e s / s u b -
ject/month) and in those who reported
hypoglycemia unawareness (from 6.19
to 3.68 episodes/subject/month), but the
inﬂuence of history of SH and hypoglyce-
mia unawareness was not statistically sig-
niﬁcant. Subjects from study group B
had a more signiﬁcant reduction in MH:
from 5.4 to 2.2 episodes, compared with
5.8 → 4.9 episodes for group A (F = 8.8,
P , 0.01).
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control
Several markers of glycemic control de-
rived from SMBG data improved as a
result of the feedback provided to the
patients. Speciﬁcally, in subjects with
baseline HbA1c $8, average glucose was
reduced from 196.4 to 187.2 mg/dL (F =
6.4, P = 0.013), the percent SMBG value
.180 mg/dL was reduced from 50.1 to
45.8% (F = 8.23, P = 0.005), and the BG
range was reduced from 183.8 to 168.1
mg/dL (F = 8.85, P = 0.04). Here, all sig-
niﬁcance levels reﬂect the interaction
effect (baseline vs. end of study) X (low-
high baseline HbA1c). A multivariate test
of signiﬁcance including all three varia-
bles resulted in F = 21.0, P , 0.001, in-
dicating signiﬁcant overall reduction in
hyperglycemia, which was consistent
with the observed reduction in HbA1c.
Blood glucose awareness and
subjective detection of hypoglycemia
T h el a s ts t a g eo ft h es t u d yp e r m i t t e dt h e
direct comparison of level 1 versus level 3
feedback (which included symptom rat-
ings), used to assess the effectiveness of
level 3 feedback on subjects’ awareness of
their BG level. Subjects’ Accuracy Index
increased from 21 to 24% from pre- to
post-level 3, whereas the Accuracy Index
onSMBGalonedecreasedfrom31to26%
(F=6.2,P=0.015).Similarly,thepercent
detection increased from 35 to 44% from
pre-topost-level3anddecreasedfrom44
to 41% from pre- to post-SMBG: F = 3.0,
P,0.05,one-tail.Thesedatasuggestthat
the reduction in MH/SH may be accom-
panied, or prompted by, a better subjec-
tive BG evaluation.
Subjective ratings of feedback
For HbA1c feedback (Questions Q1 and
Q2 under RESEARCH DESIGN AND METHODS),
therewere82%and89%“Yes”responses,
respectively, and no difference between
participants with HbA1c ,8.0/.8.0
(80% vs. 84%, respectively). For glucose
variability feedback (Questions Q3 and
Q4), 61% and 75% of participants re-
sponded “Yes,” with signiﬁcantly more
“Yes” responses in those with HbA1c
.8.0 (79% vs. 71% for Q4), indicating
that this feedback was important for sub-
jects in poor glycemic control. For risk of
hypoglycemia feedback (Questions Q5
and Q6), 51% and 42% of participants
responded “Yes.” However, among those
with history of SH, the utility of this
feedback was rated much higher, with
85% and 70% “Yes” responses, indicating
that hypoglycemia risk feedback was im-
portant for subjects at higher risk for SH.
CONCLUSIONS—The challenge for
any treatment designed to improve gly-
cemic status in type 1 diabetes is to ﬁnd a
way to reduce the frequency of hypergly-
cemia(andtherebyimproveHbA 1c)while
simultaneously avoiding an increase in
the frequency of hypoglycemia (and
therebynotworsening risk forSH).These
ﬁndings demonstrate that an automated
bio-behavioral feedback intervention, de-
livered in the ﬁeld, via an HHC, may be
able to achieve this goal. Notably, this
type of automated intervention was
most effective for those patients most at
risk for poor glucose control and prob-
lematic SH, reducing HbA1c in those
with baseline HbA1c .8.0, and reducing
the incidence of SH among those with a
historyofSH. Althoughtheimprovement
in HbA1c was less than the 1% decrease
typically accepted as clinically meaningful,
it is worth noting that the reduction for
patients in poor control was comparable
to the degree of improvement achieved by
contemporary studies using continuous
glucose monitoring (CGM) (24). The re-
duction in frequency of SH was clinically
signiﬁcant.
Studies have demonstrated the efﬁ-
cacy of behavioral interventions, such
as BGAT, in improving glucose control,
including reductions in HbA1c and the
frequency of SH episodes (9,10). How-
ever, these interventions are labor- and
resource-intensive, typically involving
multiple face-to-face training sessions
usually led by expert personnel who
have to undergo specialty training in the
delivery of the treatment program. Al-
though BGAT has been operationalized
as an Internet-based intervention (25),
issues of wide-scale dissemination and
long-term sustainability remain a chal-
lenge. Web-based systems can offer
comprehensive content, immersive expe-
rience, and great avenues for training and
information delivery. However, a simple
automated bio-behavioral feedback sys-
tem,suchastheonedevelopedandtested
inthisstudy,mayprovideamoreeffective
alternative, or complementary, method
for delivering and disseminating this
type of intervention. Such a system has
low computational demand and can be
built directly in contemporary SMBG de-
vices, which have adequate computing
power to handle the calculations needed
Figure 1—A: Reduction of A1C (HbA1c) throughout the study. Level 1 feedback (SMBG alone)
accountsfor most ofthe improvements in HbA1c. The beneﬁcial effects of the study are conﬁnedto
those with baseline HbA1c .8.0; the rest of the subjects did not change their average glycemic
control. The included signiﬁcance levels refer to comparisons involving all subjects. B: Incidence
of severe hypoglycemic was signiﬁcantly reduced as a result of the study. However, the initial
feedback from SMBG alone increased SH, and only more extensive feedback (levels 2 and 3) was
ableto reducethe incidenceof SH.The included signiﬁcancelevelsrefer to comparisonsinvolving
all subjects. Although HbA1c can be improved by intensive SMBG, simultaneous improvement in
both HbA1c and incidence of SH requires more extensive feedback to the patients. SH, severe
hypoglycemia.
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iability, risks for hypoglycemia, and asso-
ciated symptoms. The advantages of
such a system would include the follow-
ing:1)real-timefeedbackavailableimme-
diately after each SMBG reading, without
theneedtotransferSMBGdataelsewhere;
2) real-time goal setting based on esti-
mates of HbA1c or risk for hypoglycemia
and opportunities for immediate treat-
ment adjustment if an increased risk for
hypoglycemia is indicated; and 3) educa-
tional experience allowing the person to
relate self-treatment behaviors to changes
inweeklyormonthlymarkersofglycemic
control.
This last point is particularly impor-
tantbecausethecurrentsystemsgenerally
allow for relating a treatment action to its
immediate consequences captured by an
SMBG reading, but not to longer-term
effects that are reﬂected by summary
characteristics. The results of this study
support the notion that knowledge of
longer-term consequences of diabetes
management behaviors isbeneﬁcial:Rou-
tine SMBG alone (level 1) was useful for
reducing HbA1c in those patients with
poor control, which suggests that simply
increasing awareness of frequent hyper-
glycemia can sometimes be beneﬁcial for
this patient group. However, this level of
feedback was not effective in reducing
risk of SH, which did not occur until after
both level 2 and 3 feedback was received.
We can therefore speculate that higher-
leveldata processing(andperhapsbehav-
ioral responses to data feedback) is
needed to anticipate and prevent hypo-
glycemic episodes. In addition, by com-
paring level 3 with level 1 feedback, we
found that subjects’awareness of theirBG
levels decreased when real-time feedback
about their symptoms was discontinued,
which indicates that continuous engage-
ment with feedback would be needed to
maintain the intervention effect.
In addition to the objectively mea-
sured positive effect of feedback, the
participants’ opinions about the per-
ceived beneﬁts of the feedback were pos-
itive. As would be expected, real-time
estimation of HbA1c had the highest ap-
proval rating of all estimates included in
the feedback, because HbA1c is the best
known metric of glycemic control, with
89%ofthe participants wantingthisfeed-
back on a weekly basis. Feedback about
glucose variabilitywasalso wellaccepted,
with75%ofallpatients(and79%ofthose
with high baseline HbA1c) wanting this
feedback weekly. However, the positive
ratings for variability were lower than
those of HbA1c feedback, indicating that
more in-depth training or patient educa-
tion would be needed to clarify the mean-
ing and the importance of glucose
variability for maintaining glycemic con-
trol.The feedback aboutrisk for hypogly-
cemia was rated highly by those with a
history of SH, 81% of whom stated that
they would look at this feature regularly.
The rest of the patients, however, found
little beneﬁt in this type of feedback, in-
dicating that such a feature should be of-
fered only to those in need of risk
assessment. Although these positive re-
sponses are promising, future population-
based studies are needed to determine
whether patients would use and beneﬁt
from this type of automated feedback in
clinical settings.
More research is also obviously
needed to test additional types of auto-
mated feedback that might further im-
proveglucosecontrolandreduceSHrisk,
as well as other ways to optimize the
effectiveness of these interventions. Fur-
thermore, this study did not clarify a
relevant question: how participants used
the feedback at each level. Subjects were
givenwritteninstructionsonthemeaning
of the presented parameters (e.g., esti-
mated HbA1c, risk for hypoglycemia), as
well as general advice on measures that
could be taken to improve HbA1c or re-
ducerisksforhypoglycemia,butwerenot
asked to change their treatment on the
basis of the presented parameters. More-
over,therewerenospeciﬁcrecommenda-
tionsaboutanychangesininsulindosing.
Therefore, we can assume that providing
glucose proﬁle feedback on certain
longer-term summary characteristics
thatgobeyond theinformationcontained
i nas i n g l eS M B Gr e a d i n gw a su s e f u l .A
similar effect was recently reported in a
large trial of CGM; it was unclear how
subjects interpreted CGM information,
but the effect of receiving CGM feedback
wassigniﬁcant(24).Itisthereforeevident
that future research needs to focus on
how patients are using additional glucose
feedback and what types of changes are
occurring in diabetes management to im-
prove outcome.
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